Exposure of rats to continuous light attenuates melatonin production and results in hypertension development. This study investigated whether hypertension induced by continuous light (24 hours/day) exposure induces heart and aorta remodelling and if these alterations are prevented by melatonin or angiotensin converting enzyme inhibitor captopril. Four groups of 3-month-old male Wistar rats (10 per group) were treated as follows for six weeks: untreated controls, exposed to continuous light, light-exposed, and treated with either captopril (100 mg/kg/day) or melatonin (10 mg/kg/day). Exposure to continuous light led to hypertension, left ventricular (LV) hypertrophy and fibrosis, and enhancement of the oxidative load in the LV and aorta. Increase in systolic blood pressure by continuous light exposure was prevented completely by captopril and partially by melatonin. Both captopril and melatonin reduced the wall thickness and cross-sectional area of the aorta and reduced the level of oxidative stress. However, only captopril reduced LV hypertrophy development and only melatonin reduced LV hydroxyproline concentration in insoluble and total collagen in rats exposed to continuous light. In conclusion, captopril prevented LV hypertrophy development in the continuous light-induced hypertension model, while only melatonin significantly reduced fibrosis. This antifibrotic action of melatonin may be protective in hypertensive heart disease.

1. Introduction

Left ventricular (LV) hypertrophy, although representing an adaptation to hemodynamic overload, is associated with increased cardiovascular risk [1, 2]. The search for new approaches for the prevention or regression of LV hypertrophy in different models of pathological myocardial growth continues [3–7].

Melatonin (N-acetyl-5-methoxytryptamine), the most abundant secretory product of the vertebrate pineal gland that controls biological rhythms [8], has numerous beneficial actions in the heart [9–12] and plays an important role in the pathogenesis of hypertension [13–16]. Experimental pinealectomy, a procedure that is easily performed in rats [17], reduced the level of both day-time and nocturnal melatonin [8] and resulted in an enhancement of vascular responsiveness to vasoconstriction stimuli [18], increased blood pressure, and myocardial fibrosis [19]. An alternative approach to attenuate melatonin production, associated with a blood pressure rise, is the exposure of rats to continuous 24 hours/day chronic lighting [20]. This model of melatonin-deficient hypertension seems to be more physiological than...
pinealectomy because it reduces only nocturnal melatonin secretion and no surgery is involved [20]. Since melatonin exerts cardiovascular protection on several levels including antioxidant and scavenging actions [21–23], endothelial protection, sympatholytic effect [24–28], and antiarrhythmic effects [29], it is comprehensible that a deficiency of melatonin could result in pathological alterations in circulation and target organ damage [2, 8]. Indeed, several studies with patients suffering from acute myocardial infarction with ST segment elevation indicated that deficit of melatonin could be a negative prognostic factor of the severity of infarction, subsequent remodelling, and prognosis [30–33] and that melatonin supplementation may exert beneficial effects as a radical scavenger in a human model of myocardial ischemia-reperfusion damage [34, 35].

This study investigated whether continuous light-induced hypertension results in the pathological growth of the heart and the aorta and whether melatonin can modify these potential alterations. Moreover, the effect of melatonin was compared with the angiotensin converting enzyme (ACE) inhibitor, captopril. Since ACE-inhibitors are antihypertensives with well-established antihypertrophic effect, which is also based on inhibition of angiotensin II production and interference with aldosterone, catecholamines, or endothelin production [37, 38], ACE-inhibition may be protective also in continuous light-induced hypertension.

2. Material and Methods

2.1. Animals and Treatment. Male adult three-month-old Wistar rats (Dobra Voda, Slovak Republic) were randomly divided into four groups (n = 10 in each group): control (Wistar) rats (c), rats exposed to 24 hours/day continuous light (24), and continuous light-exposed rats treated with either captopril (100 mg/kg/day; Egis Pharmaceuticals Ltd, Budapest; 24C) or melatonin (10 mg/kg/day; Sigma Chemical Co., Deisenhofen, Germany; 24M). Captopril and melatonin were dissolved in drinking water and their concentration was adjusted to daily water consumption to ensure correct dosage. The natural water consumption of rats was about 12–13 mL/100 g of body weight. In order to ensure that all the amount of water with dissolved melatonin was really drank by a particular rat, only 10 mL/100 mg of water-melatonin solution was offered. The solution was prepared as follows: 10 mg of melatonin was dissolved in 100 mL water, while no additional substance was added to dissolve the substance. Melatonin containing solutions were protected from light exposure by using black bottles. All rats were housed in individual cages at 22–24°C and fed a regular pellet diet ad libitum in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication number 8523, revised 1985).

Systolic blood pressure (SBP) was measured each week by noninvasive tail-cuff plethysmography (Hugo-Sachs Electronic, Freiburg, Germany). After six weeks, rats were decapitated and body weight (BW), heart weight (HW), and LV and right ventricle weights (LVW, RVW) were determined and their relative weights (LVW/BW and RVW/BW ratio) were calculated. Left ventricle samples were frozen at −80°C and later used for the determination of hydroxyproline concentrations and oxidative stress parameters.

2.2. Morphometry of Aorta. Thoracic aorta samples were fixed for 24 hours in 4% formaldehyde, embedded in paraffin, cut in serial 5 μm thick sections, and stained with haematoxylin and eosin. Wall thickness (WT) in μm and the inner circumference in mm were measured using light microscopy and a two-dimensional image analyzer (Impor Pro; Krant s.r.o., Bratislava, Slovak Republic). Inner diameter (ID) expressed in mm and cross-sectional area (CSA) expressed in mm² were then calculated [28]. During morphometric measurements the observer was blinded (only the numbers of animals were accessible for the observer).

2.3. Determination of Hydroxyproline. Collagenous proteins were isolated according to Pelouch et al. [39, 40]. Hydroxyproline concentrations were analyzed spectrophotometrically at 550 nm [41].

2.4. Oxidative Load Measurement. Tissue samples were homogenized in 1 mL phosphate buffered saline and centrifuged at 19320 g (4°C) for 5 minutes and the supernatant was used for further biochemical analyses.

Advanced glycation end-products (AGEs) as markers of carbonyl stress were measured using the characteristic fluorescence (λex. = 370 nm, λem. = 440 nm) [42]. Briefly, tissue homogenates were diluted 10-fold with phosphate buffered saline and the AGEs concentration was calculated based on the calibration curve prepared with AGE-BSA calibrator [43]. Advanced oxidation protein products (AOPP) were determined spectrophotometrically [44]. Briefly, 200 μL of appropriately diluted tissue homogenates were incubated with glacial acetic acid for 2 minutes and the absorbance was read at 340 nm using Sapphire II instrument (Técan, Grödig, Austria). AOPP concentration was calculated on the basis of the calibration curve of chloramin T with potassium iodide. Proteins were quantified using BCA protein assay kit (Sigma Aldrich, Steinheim, Germany) [42].

2.5. CoQ and Tocopherol Measurement. Concentrations of CoQ9ox, CoQ10ox, and gamma- and alpha-tocopherol were determined by HPLC method according to Lang et al. [45] with some modifications [46]. Concentrations of CoQ and tocopherols were detected spectrophotometrically at 275 nm and 295 nm, respectively.

2.6. Statistical Analysis. Results are expressed as mean ± S.E.M. One-way, two-tailed analysis of variance (ANOVA) and the Bonferroni test were used for statistical analysis. Differences were considered significant if the P value < 0.05.

3. Results

3.1. Cardiovascular Parameters. SBP was 125 ± 0.79 mmHg in control rats and 163 ± 0.48 mmHg in continuous light-group. SBP decreased significantly (P < 0.05) by both captopril (21%) and melatonin (15%) treatment compared
to continuous light-group (Figure 1(a)). The LVW/BW ratio after six weeks of treatment was 1.08 ± 0.04 mg/g and 1.27 ± 0.05 mg/g, in the control and continuous light-group, respectively. Captopril decreased the LVW/BW ratio (30%, $P < 0.05$), while melatonin had no effect (Figure 1(b)). Absolute left ventricular weight was also affected only by the captopril treatment (Table 1).

### 3.3. Hydroxyproline in the Soluble and Insoluble Collagen and Total Hydroxyproline in the LV

Hydroxyproline concentration in the soluble collagenous protein was 0.14 ± 0.004 mg/g and 0.152 ± 0.005 mg/g in the control and continuous light-groups, respectively. Neither captopril nor melatonin had any effect on hydroxyproline concentration in soluble collagen (Figure 3(a)).

Hydroxyproline concentration in the insoluble collagen was 0.540 ± 0.024 mg/g and 0.690 ± 0.029 mg/g in the control and continuous light-groups, respectively, and it was significantly reduced only by melatonin (20%, $P < 0.05$) (Figure 3(b)).

Total hydroxyproline concentration was 0.68 ± 0.025 mg/g and 0.830 ± 0.020 mg/g in the control and continuous light-groups, respectively, and it was reduced only by melatonin (15%, $P < 0.05$) (Figure 3(c)).
4 Mediators of Inflammation

Figure 3: The influence of captopril (24C) and melatonin (24M) on hydroxyproline concentration in soluble (a) and insoluble (b) collagen proteins and on total hydroxyproline concentration (c) in 24 hours/day continuous light exposure-induced hypertension (24). c: Wistar controls. *P < 0.05 versus c; #P < 0.05 versus 24.

Table 1: The body weight (BW), right ventricle weight (RVW), relative RVW (RVW/BW), and left ventricle weight (LVW) in control rats (c), rats exposed to 24 h/day continuous light without treatment (24), and rats treated with captopril (24C) and melatonin (24M).

|          | BW (g)   | RVW (mg) | RVW/BW (mg/g) | LVW (mg) |
|----------|----------|----------|---------------|----------|
| c        | 442.5 ± 14.9 | 201.7 ± 10.0 | 0.45 ± 0.01 | 478.9 ± 21.1 |
| 24       | 392.8 ± 8.6* | 214.7 ± 6.3 | 0.55 ± 0.02* | 498.2 ± 24.8 |
| 24C      | 402.3 ± 11.6 | 155.1 ± 8.5** | 0.39 ± 0.02** | 361.9 ± 19.0** |
| 24M      | 388.2 ± 11.6* | 160.5 ± 10.3** | 0.41 ± 0.03** | 485.6 ± 13.4 |

Values are mean ± SEM, *P < 0.05 versus c, **P < 0.05 versus 24.

3.4. Oxidative Stress Parameters. The LV AOPP was 5.01 ± 0.32 μmol/g prot. and 6.38 ± 0.52 μmol/g prot. in the control and continuous light-groups, respectively, and both captopril and melatonin significantly reduced AOPP in the LV (28%, P < 0.05 and 30%, P < 0.05, resp.) (Figure 4(a)). The aortic AOPP was 25.72 ± 1.52 μmol/g prot. and 33.11 ± 1.10 μmol/g prot. in the control and continuous light-groups, respectively, and both captopril and melatonin significantly reduced AOPP in the aorta (48%, P < 0.05 and 19%, P < 0.05, resp.) (Figure 4(b)). The aortic AGEs were 0.43 ± 0.06 and 0.47 ± 0.04 in the control and continuous light-groups, respectively. Both captopril and melatonin significantly reduced AGEs in the aorta (34%, P < 0.05 and 30%, P < 0.05, resp.) (Figure 4(d)).

3.5. CoQ and Tocopherol. The left ventricular CoQ9ox, CoQ10ox, and alpha-tocopherol levels were not changed in either group. Gamma-tocopherol concentration in the LV was decreased in the continuous light-group and neither captopril nor melatonin modified it (Table 2).

4. Discussion

Under physiological conditions in humans, melatonin concentration is low during the day, but it is much higher at night and is accompanied by lowering of the nocturnal blood pressure [47]. The evening rise in melatonin represents an important part of suprachiasmatic adaptation to the rest
and activity periods [48, 49]. Inhibition of the nighttime rise in melatonin by continuous light exposure in rats [20] mimics the melatonin profile of patients with nondipping blood pressure profile [26], in which an insufficient rise in 6-sulphamethoxymelatonin in urine reflects a blunted increase in serum melatonin during the night period [50]. This functional pinealectomy in rats results in gradually developing hypertension [51], although the blood pressure rise is less pronounced than in L-NAME [37, 52] or spontaneously hypertensive rat (SHR) [38] models of experimental hypertension.

In rats exposed to constant lighting, hypertension development was associated with a rise in the LV weight, whereas no changes in the wall thickness and cross-sectional area of the aorta were observed. Interestingly, captopril inhibited the rise in blood pressure completely, reduced the LV weight even below the control values, similarly as was shown in SHR model [38], and reduced the aortic wall thickness and cross-sectional area (Figures 2(a), 2(b), and 5). Melatonin, like captopril, also reduced blood pressure and the aortic wall thickness and cross-sectional area (Figures 2(a), 2(b), and 5). However, unlike captopril, melatonin had no effect on the weight of the LV, similarly as has been reported in L-NAME-hypertension [53]. These observations suggest that hypertrophic growth of the LV and of the aorta are differently controlled in this particular model.
Fibrotic LV remodelling after six-week exposure to constant light was characterized by elevated hydroxyproline levels in the insoluble (maturated, more cross-linked) and in total collagen (the sum of soluble and insoluble collagens). Only melatonin significantly reduced hydroxyproline concentration in both insoluble and total collagen. In a previous experiment with a combination of continuous light plus L-NAME model of hypertension analogous protection by melatonin was achieved [51]. Despite the increase of blood pressure and that fibrosis was even more pronounced in a continuous light plus L-NAME hypertension than in the continuous light model, melatonin reduced blood pressure and fibrosis in a similar way as in this experiment and also without attenuation of LV hypertrophy [51]. Moreover, this fibrosis-reducing effect of melatonin was confirmed in SHR model [38]. The indolamine also reduced the accumulation of collagens I and III in the aorta in continuous light-induced hypertension [36] (Figures 6 and 7). Since the quality rather than the quantity of the hypertrophied myocardium is important, while fibrosis is one of the decisive negative prognostic factors [54], this antifibrotic effect of melatonin may be of importance in patients with hypertensive heart.

Different impacts of melatonin and captopril treatment on the LV hypertrophy and LV fibrosis need to be addressed. It is generally accepted that LV hypertrophy development or its regression is mainly determined by the level of haemodynamic burden. Thus, the fact that only captopril reduced LV weight may be driven by a more prominent reduction in blood pressure by captopril than by melatonin. The distinct effects of captopril and melatonin on the LV fibrosis may be related to the complexity of hypertension development in this particular model and by the pleiotropic actions of both drugs. Fibrosis development is mainly dependent on the humoral disbalance between oxidative load, pro-proteosynthetic, and pro-proliferative factors such as angiotensin II, aldosterone, endothelin, or catecholamines on the one side and substances with growth attenuating potential, such as nitric oxide (NO), prostacyclin, or atrial natriuretic peptide [54–56] on the other side. Continuous light-induced hypertension development is obviously associated with more complex neurohumoral...
The important question is the dose of captopril and melatonin that should be chosen to counteract pathological alterations of the continuous light-induced hypertension and LVH. 100 mg/kg/day of captopril [36, 38, 51] and 10 mg/kg/day of melatonin [38, 51, 53] used in our previous works were shown to lower increased blood pressure and protect the cardiovascular system against deleterious effect of hemodynamic overload. Moreover, the higher dose of captopril (150 mg/kg/day), which was tested in our pilot studies, was not well tolerated, as convulsions of striated muscles occurred as a result of hyperkalemia. Analogically, higher doses of melatonin were shown to have sedative effects. Thus, the tolerable pharmacological dose of captopril (100 mg/kg/day) and melatonin (10 mg/kg/day) may be sufficient to induce the potential protective effects of tested substances.

The choice of captopril from the large group of accessible ACE-inhibitors was determined by three points. First, captopril is considered to be the gold standard, since it was the first ACE-inhibitor approved by Food and Drug Administration in 1993 as an effective treatment of heart remodeling and failure. Second, captopril contains SH group with potentially beneficial effect against oxidative stress. Third, in our previous experiments captopril was used [4, 36–38, 51] and thus the presented data of this experiment may be compared with our previous results from other models of hypertension.
It should be emphasized that in this experiment three-month-old rats (which may be considered to be adult) were used in a "preventive" experiment. However, when substantially younger rats with developing LVH and fibrosis were used, the results could be different.

In conclusion, captopril prevented LV hypertrophy development in the continuous light-induced hypertension model but only melatonin significantly reduced fibrosis. This antifibrotic action of melatonin may be protective in hypertensive heart disease.

5. Limitations of the Work

In the model of continuous light exposure it would be of benefit to assess blood pressure more accurately by using telemetry system or by making measurements every 12 hours by tail-cuff plethysmography to disclose circadian rhythms of blood pressure. Moreover, it would be useful to investigate the group with continuous light and combination of captopril + melatonin treatment to show the potential complementary protection of both drugs. Furthermore, it may be useful to compare biochemical determination of the collagen level in the LV with the histochemical method, similarly as to know the level of NOx (nitrite-nitrate). However, these approaches were beyond the scope and possibilities of this experiment.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This work was supported by the Scientific Grant Agency of the Ministry of Education (VEGA 1/0227/12, 2/00183/12), the Agency for Science and Technique (APVV-0742-10) and by the program PRVOUK P37/5.

References

[1] R. J. Reiter, L. C. Manchester, L. Fuentes-Broto, and D. Tan, "Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin," *Journal of Hypertension*, vol. 28, no. 1, pp. 57–62, 2010.
Mediators of Inflammation

[2] F. Simko and O. Pechanova, “Remodelling of the heart and vessels in experimental hypertension: advances in protection,” Journal of Hypertension, vol. 28, supplement 1, pp. S1–S6, 2010.

[3] F. Simko, J. Matuskova, I. Luptak et al., “Effect of simvastatin on remodelling of the left ventricle and aorta in L-NAME-induced hypertension,” Life Sciences, vol. 74, no. 10, pp. 1211–1224, 2004.

[4] F. Simko, V. Pelouch, J. Torok et al., “Protein remodeling of the heart ventricles in hereditary hypertriglyceridemic rat: effect of ace-inhibition,” Journal of Biomedical Science, vol. 12, no. 1, pp. 103–111, 2005.

[5] C. A. Mandarim-de-Lacerda and L. M. M. Pereira, “Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats,” Histology and Histopathology, vol. 19, no. 3, pp. 727–733, 2004.

[6] F. Simko, “Statins: a perspective for left ventricular hypertrophy treatment,” European Journal of Clinical Investigation, vol. 37, no. 9, pp. 681–691, 2007.

[7] J. Kyselovic, P. Krenek, M. Wibo, and T. Godfraind, “Effects of amiodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats,” The British Journal of Pharmacology, vol. 134, no. 7, pp. 1516–1522, 2001.

[8] F. Simko, R. J. Reiter, O. Pechanova, and L. Paulis, “Experimental models of melatonin-deficient hypertension,” Frontiers in Bioscience, vol. 18, no. 2, pp. 616–625, 2013.

[9] M. Ozturk, M. Ozler, Y. G. Kurt et al., “Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity,” Journal of Pineal Research, vol. 50, no. 1, pp. 89–96, 2011.

[10] E. Grossini, C. Molinari, F. Uberti, D. A. S. G. Mary, G. Vacca, and F. P. Caizimi, “Intracoronary melatonin increases coronary blood flow and cardiac function through β-adrenoreceptors, MT1/MT2 receptors, and nitric oxide in anesthetized pigs,” Journal of Pineal Research, vol. 51, no. 2, pp. 246–257, 2011.

[11] S. Samimi-Fard, P. Abreu-Gonzalez, A. Dominguez-Rodriguez, and A. Jimenez-Sosa, “A case-control study of melatonin receptor type 1A polymorphism and acute myocardial infarction in a Spanish population,” Journal of Pineal Research, vol. 51, no. 4, pp. 400–404, 2011.

[12] M. Zeman and I. Herichova, “Melatonin and clock genes expression in the cardiovascular system,” Frontiers in Bioscience, vol. 1, no. 5, pp. 743–753, 2013.

[13] F. Simko and L. Paulis, “Melatonin as a potential antihypertensive treatment,” Journal of Pineal Research, vol. 42, no. 4, pp. 319–322, 2007.

[14] S. Tengattini, R. J. Reiter, D. Tan, M. P. Terron, L. F. Rodella, and R. Rezzani, “Cardiovascular diseases: protective effects of melatonin,” Journal of Pineal Research, vol. 44, no. 1, pp. 16–25, 2008.

[15] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, J. J. Sanchez-Sanchez, J. C. Kaski, and R. J. Reiter, “Melatonin and circadian biology in human cardiovascular disease,” Journal of Pineal Research, vol. 49, no. 1, pp. 14–22, 2010.

[16] L. Paulis and F. Šimko, “Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind,” Physiological Research, vol. 56, no. 6, pp. 671–684, 2007.

[17] R. A. Hoffman and R. J. Reiter, “Rapid pinealocyte in hamsters and other small rodents,” The Anatomical Record, vol. 153, no. 1, pp. 19–21, 1965.

[18] S. C. Cunnane, M. S. Manku, M. Oka, and D. F. Horrobin, “Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin,” Canadian Journal of Physiology and Pharmacology, vol. 58, no. 3, pp. 287–293, 1980.

[19] A. Zanoboni and W. Zanoboni-Muciacia, “Experimental hypertension in pinealectomized rats,” Life Sciences, vol. 6, no. 21, pp. 2327–2331, 1967.

[20] G. M. Brown, A. Bar-Or, D. Grossi, S. Kashur, and E. Johansson, “Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat,” Journal of Pineal Research, vol. 10, no. 3, pp. 141–147, 1991.

[21] D. X. Tan, L. D. Chen, B. Poeppelger et al., “Melatonin: a potent, endogenous hydroxyl radical scavenger,” Endocrine Journal, vol. 1, pp. 157–160, 1993.

[22] R. J. Reiter, D. X. Tan, M. P. Terron, L. J. Flores, and Z. Czarnocki, “Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions,” Acta Biochimica Polonica, vol. 54, no. 1, pp. 1–9, 2007.

[23] A. Galano, D. X. Tan, and R. J. Reiter, “Melatonin as a natural ally against oxidative stress: a physicochemical examination,” Journal of Pineal Research, vol. 51, no. 1, pp. 1–16, 2011.

[24] R. J. Reiter and D. X. Tan, “Melatonin: a multitasking molecule,” Progress in Brain Research, vol. 181, pp. 127–151, 2010.

[25] R. Rezzani, E. Porteri, C. de Ciuceis et al., “Effects of melatonin and pycnogenol on small artery structure and function in spontaneously hypertensive rats,” Hypertension, vol. 55, no. 6, pp. 1373–1380, 2010.

[26] R. J. Reiter, D. Tan, and A. Korkmaz, “The circadian melatonin rhythm and its modulation: possible impact on hypertension,” Journal of Pineal Research, vol. 27, supplement 6, pp. S17–S20, 2009.

[27] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and R. J. Reiter, “Melatonin and cardiovascular disease: myth or reality?” Revista Española de Cardiología, vol. 65, no. 3, pp. 215–218, 2012.

[28] L. Paulis, J. Matuskova, M. Adamcova et al., “Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone,” Acta Physiologica, vol. 194, no. 1, pp. 45–55, 2008.

[29] T. Benova, C. Viczenczova, J. Radosinska et al., “Melatonin attenuates hypertension-related proarrhythmic myocardial maladaptation of connexin-43 and propensity of the heart to lethal arrhythmias,” Canadian Journal of Physiology and Pharmacology, vol. 91, no. 8, pp. 633–639, 2013.

[30] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, M. Garcia-Gonzalez, and R. J. Reiter, “Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction,” The American Journal of Cardiology, vol. 97, no. 8, pp. 1162–1164, 2006.

[31] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, R. J. Reiter, “Clinical aspects of melatonin in the acute coronary syndrome,” Current Vascular Pharmacology, vol. 7, no. 3, pp. 367–373, 2009.

[32] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, E. Arroyo-Ucar, and R. J. Reiter, “Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction,” Journal of Pineal Research, vol. 53, no. 3, pp. 319–323, 2012.

[33] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, E. Arroyo-Ucar, P. Avanzas, and R. J. Reiter, “Global left ventricular longitudinal strain is associated with decreased melatonin levels in patients with acute myocardial infarction: a two-dimensional speckle tracking study,” Biomarkers, vol. 18, no. 4, pp. 310–313, 2013.
myocardial Infarction undergoing primary Angioplasty. The Melatonin Adjunct in the acute myocardial Infarction treated with Angioplasty (Maria) trial: study design and rationale,” Contemporary Clinical Trials, vol. 28, no. 4, pp. 532–539, 2007.

[35] A. Domínguez-Rodríguez, P. Abreu-González, and R. J. Reiter, “Melatonin and cardioprotection in the acute myocardial infarction: a promising cardioprotective agent,” International Journal of Cardiology, vol. 158, no. 2, pp. 309–310, 2012.

[36] K. Repova-Bednarova, S. Aziriova, and J. Hrenak, “Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension,” Physiological Research, vol. 62, supplement 1, pp. S135–S141, 2013.

[37] I. Bernátová, O. Pechánová, V. Pelouch, and F. Šimko, “Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 2, pp. 177–185, 2000.

[38] F. Šimko, O. Pechanova, V. Pelouch et al., “Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats,” Journal of Hypertension, vol. 27, supplement 6, pp. S5–S10, 2009.

[39] V. Pelouch, M. Milorova, B. Ostadal, M. Samanek, and B. Hucin, “Protein profiling of human atrial and ventricular musculature: the effect of normoxaemia and hypoxaemia in congenital heart diseases,” Physiological Research, vol. 42, no. 4, pp. 235–242, 1993.

[40] V. Pelouch, M. Milorova, B. Ostadal, B. Hucin, and M. Samanek, “Differences between atrial and ventricular protein profiling in children with congenital heart disease,” Molecular and Cellular Biochemistry, vol. 147, no. 1–4, pp. 43–49, 1995.

[41] G. K. Reddy and C. S. Enwemeka, “A simplified method for the analysis of hydroxyproline in biological tissues,” Clinical Biochemistry, vol. 29, no. 3, pp. 225–229, 1996.

[42] G. Munch, R. Keis, A. Wessels et al., “Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 35, no. 9, pp. 669–677, 1997.

[43] A. D. Bhatwadekar and V. S. Ghole, “Rapid method for the preparation of an AGE-BSA standard calibrator using thermal glycation,” Journal of Clinical Laboratory Analysis, vol. 19, no. 1, pp. 11–15, 2005.

[44] V. Witko-Sarsat, M. Friedlander, C. Capeillère-Blandin et al., “Advanced oxidation protein products as a novel marker of oxidative stress in uremia,” Kidney International, vol. 49, no. 5, pp. 1304–1313, 1996.

[45] J. K. Lang, K. Gohil, and L. Packer, “Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions,” Analytical Biochemistry, vol. 157, no. 1, pp. 106–116, 1986.

[46] J. Kucharska, A. Gvozdjaková, and F. Simko, “Simvastatin decreased coenzyme Q in the left ventricle and skeletal muscle but not in the brain and liver in L-NAME-induced hypertension,” Physiological Research, vol. 56, supplement 2, pp. S49–S54, 2007.

[47] M. Zeman, K. Kučíková, V. Bada, and J. Herichová, “Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile,” Life Sciences, vol. 76, no. 16, pp. 1795–1803, 2005.

[48] R. M. Buijs and A. Kalbeek, “Hypothalamic integration of central and peripheral clocks,” Nature Reviews Neuroscience, vol. 2, no. 7, pp. 521–526, 2001.

[49] F. A. J. Scheer, G. A. van Montfrans, E. J. W. van Someren, G. Mairuhu, and R. M. Buijs, “Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension,” Hypertension, vol. 43, no. 2, pp. 192–197, 2004.

[50] M. Jonas, D. Garfinkel, N. Zissapel, M. Laudon, and E. Grossman, “Impaired nocturnal melatonin secretion in non-dipper hypertensive patients,” Blood Pressure, vol. 12, no. 1, pp. 19–24, 2003.

[51] F. Simko, O. Pechanova, V. Pelouch et al., “Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril,” Journal of Hypertension, vol. 28, supplement 1, pp. S13–S18, 2010.

[52] O. Pechánová, Z. Zichová, and L. Paulis et al., “The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension,” European Journal of Pharmacology, vol. 561, no. 1–3, pp. 129–136, 2007.

[53] L. Paulis, O. Pechanova, J. Zichová et al., “Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats,” Journal of Hypertension, vol. 27, supplement 6, pp. S11–S16, 2009.

[54] K. T. Weber, “From inflammation to fibrosis: a stiff stretch of highway,” Hypertension, vol. 43, no. 4, pp. 716–719, 2004.

[55] F. Simko and J. Simko, “The potential role of nitric oxide in the hypertrophic growth of the left ventricle,” Physiological Research, vol. 49, no. 1, pp. 37–46, 2000.

[56] F. Simko, “Is NO the king? Pathophysiological benefit with uncertain clinical impact [editorial],” Physiological Research, vol. 56, supplement 2, pp. S1–S6, 2007.

[57] H. Karpfpanen, S. Lahovaara, P. Männistö, and H. Vapaatalo, “Plasma renin activity and in vitro synthesis of aldosterone by the adrenal glands of rats with spontaneous, renal, or pinealocytemy induced hypertension,” Acta Physiologica Scandinavica, vol. 94, no. 2, pp. 184–188, 1975.

[58] V. Milosivic, S. Trifunovic, M. Sekulic et al., “Chronic exposure to constant light affects morphology and secretion of adrenal zona fasciculata cells in female rats,” General Physiology and Biophysics, vol. 24, no. 3, pp. 299–309, 2005.

[59] H. Li, Y. Kang, L. Yu, H. Xu, and H. Zhao, “Melatonin reduces blood pressure in rats with stress-induced hypertension viaGABAA receptors,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 4, pp. 436–440, 2009.

[60] R. J. Reiter, D. X. Tan, L. C. Manchester, M. Pilar Terron, L. J. Flores, and S. Koppisepi, “Medical implications of melatonin: receptor-mediated and receptor-independent actions,” Advances in Medical Sciences, vol. 52, pp. 11–28, 2007.

[61] M. Koziróg, A. R. Poliwczak, P. Ducha, M. Koter-Michalak, J. Sikora, and M. Broncel, “Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome,” Journal of Pineal Research, vol. 50, no. 3, pp. 261–266, 2011.

[62] F. Simko, J. Simko, and M. Fabryová, “ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle,” Cardiovascular Drugs and Therapy, vol. 17, no. 3, pp. 287–290, 2003.